

Henk M W Verheul

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/469882/henk-m-w-verheul-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

266
papers

8,012
citations

44
h-index

83
g-index

301
ext. papers

9,755
ext. citations

6.2
avg, IF

5.89
L-index

#	Paper	IF	Citations
266	Harmonising patient-access programmes: the Dutch DRUG Access Protocol platform.. <i>Lancet Oncology, The</i> , 2022 , 23, 198-201	21.7	2
265	In Patients Undergoing CRS/HIPEC for Colorectal Adenocarcinoma with Peritoneal Metastases, Presence of Ascites on Computed Tomography Imaging is not a Prognostic Marker for Survival.. <i>Annals of Surgical Oncology</i> , 2022 , 1	3.1	0
264	ASO Visual Abstract: In Patients Undergoing CRS/HIPEC for Colorectal Adenocarcinoma with Peritoneal Metastases, Presence of Ascites on Computed Tomography Imaging is Not a Prognostic Marker for Survival.. <i>Annals of Surgical Oncology</i> , 2022 , 1	3.1	
263	C-Sorafenib and O-HO PET for Early Evaluation of Sorafenib Therapy. <i>Journal of Nuclear Medicine</i> , 2021 , 62, 934-940	8.9	
262	Clinical judgment of the need for professional mental health care in patients with cancer: a qualitative study among oncologists and nurses. <i>Journal of Cancer Survivorship</i> , 2021 , 1	5.1	0
261	Sixty-Day Mortality of Patients With Metastatic Colorectal Cancer Randomized to Systemic Treatment vs Primary Tumor Resection Followed by Systemic Treatment: The CAIRO4 Phase 3 Randomized Clinical Trial. <i>JAMA Surgery</i> , 2021 , 156, 1093-1101	5.4	2
260	Diagnostic Performance of [F]FDG PET in Staging Grade 1-2, Estrogen Receptor Positive Breast Cancer. <i>Diagnostics</i> , 2021 , 11,	3.8	2
259	Enhancement of NK Cell Antitumor Effector Functions Using a Bispecific Single Domain Antibody Targeting CD16 and the Epidermal Growth Factor Receptor. <i>Cancers</i> , 2021 , 13,	6.6	1
258	Conversion of a colorectal cancer guideline into clinical decision trees with assessment of validity. <i>International Journal for Quality in Health Care</i> , 2021 , 33,	1.9	1
257	A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype. <i>Clinical and Translational Science</i> , 2021 , 14, 954-963	4.9	2
256	Interferon- and STING-independent induction of type I interferon stimulated genes during fractionated irradiation. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021 , 40, 161	12.8	4
255	Prediction of response to sunitinib in patients with advanced renal cell carcinoma (RCC) using mass spectrometry-based (phospho) proteomics.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e16556-e16556	2.2	
254	Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial. <i>JAMA Surgery</i> , 2021 , 156, 710-720	5.4	2
253	Effects of physical exercise on natural killer cell activity during (neo)adjuvant chemotherapy: A randomized pilot study. <i>Physiological Reports</i> , 2021 , 9, e14919	2.6	4
252	High-dose administration of tyrosine kinase inhibitors to improve clinical benefit: A systematic review. <i>Cancer Treatment Reviews</i> , 2021 , 97, 102171	14.4	2
251	Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1995-2004	2.2	42
250	Metoclopramide, Dexamethasone, or Palonosetron for Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting After Moderately Emetogenic Chemotherapy (MEDEA): A Randomized, Phase III, Noninferiority Trial. <i>Oncologist</i> , 2021 , 26, e173-e181	5.7	3

249	Predicting outcome in older patients with cancer: Comprehensive geriatric assessment and clinical judgment. <i>Journal of Geriatric Oncology</i> , 2021 , 12, 49-56	3.6	2
248	Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era. <i>British Journal of Cancer</i> , 2021 , 124, 399-406	8.7	8
247	A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2021 , 124, 728-735	8.7	22
246	Smartphone measurements of physical activity and fitness are associated with early trial discontinuation of patients in (hemato)oncology phase I/II clinical trials. <i>Supportive Care in Cancer</i> , 2021 , 29, 3783-3792	3.9	0
245	A Phase I Open-Label Clinical Trial Evaluating the Therapeutic Vaccine hVEGF26-104/RFASE in Patients with Advanced Solid Malignancies. <i>Oncologist</i> , 2021 , 26, e218-e229	5.7	2
244	Molecular profiles of response to neoadjuvant chemoradiotherapy in oesophageal cancers to develop personalized treatment strategies. <i>Molecular Oncology</i> , 2021 , 15, 901-914	7.9	1
243	Time dependent effect of cold ischemia on the phosphoproteome and protein kinase activity in fresh-frozen colorectal cancer tissue obtained from patients. <i>Clinical Proteomics</i> , 2021 , 18, 8	5	0
242	Natural Killer Cells and Anti-Cancer Therapies: Reciprocal Effects on Immune Function and Therapeutic Response. <i>Cancers</i> , 2021 , 13,	6.6	7
241	Limited evolution of the actionable metastatic cancer genome under therapeutic pressure. <i>Nature Medicine</i> , 2021 , 27, 1553-1563	50.5	11
240	Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types. <i>Clinical Cancer Research</i> , 2021 , 27, 6106-6114	12.9	1
239	The prognostic impact of circulating miRNAs in patients with advanced esophagogastric cancer during palliative chemotherapy. <i>Cancer Treatment and Research Communications</i> , 2021 , 27, 100371	2	0
238	Phosphotyrosine-based Phosphoproteomics for Target Identification and Drug Response Prediction in AML Cell Lines. <i>Molecular and Cellular Proteomics</i> , 2020 , 19, 884-899	7.6	13
237	Safety and Feasibility of Additional Tumor Debulking to First-Line Palliative Combination Chemotherapy for Patients with Multiorgan Metastatic Colorectal Cancer. <i>Oncologist</i> , 2020 , 25, e1195-e1201	5.7	4
236	Combination of variations in inflammation- and endoplasmic reticulum-associated genes as putative biomarker for bevacizumab response in KRAS wild-type colorectal cancer. <i>Scientific Reports</i> , 2020 , 10, 9778	4.9	1
235	The Current Status of Immune Checkpoint Inhibitors in Neuro-Oncology: A Systematic Review. <i>Cancers</i> , 2020 , 12,	6.6	28
234	Wide variation in tissue, systemic, and drain fluid exposure after oxaliplatin-based HIPEC: results of the GUTOX study. <i>Cancer Chemotherapy and Pharmacology</i> , 2020 , 86, 141-150	3.5	1
233	Muscle contractile properties of cancer patients receiving chemotherapy: Assessment of feasibility and exercise effects. <i>Scandinavian Journal of Medicine and Science in Sports</i> , 2020 , 30, 1918-1929	4.6	2
232	White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer. <i>Nature Communications</i> , 2020 , 11, 525	17.4	64

231	CD276-Positive Circulating Endothelial Cells Do Not Predict Response to Systemic Therapy in Advanced Colorectal Cancer. <i>Cells</i> , 2020 , 9,	7.9	4
230	Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Versus Surgery Without HIPEC for Goblet-Cell Carcinoids and Mixed Adenoneuroendocrine Carcinomas: Propensity Score-Matched Analysis of Centers in the Netherlands and Belgium. <i>Clinical Colorectal Cancer</i> , 2020 , 19, e87-e99	3.8	1
229	Clinical assessment of emotions in patients with cancer: Diagnostic accuracy compared with two reference standards. <i>Psycho-Oncology</i> , 2020 , 29, 775-780	3.9	4
228	Kinase Inhibitor Treatment of Patients with Advanced Cancer Results in High Tumor Drug Concentrations and in Specific Alterations of the Tumor Phosphoproteome. <i>Cancers</i> , 2020 , 12,	6.6	5
227	634 Production and testing of a novel bispecific nanobody construct targeting NK cells and EGFR expressing malignancies 2020 , 8, A670-A670		
226	Visual and quantitative evaluation of [F]FES and [F]FDHT PET in patients with metastatic breast cancer: an interobserver variability study. <i>EJNMMI Research</i> , 2020 , 10, 40	3.6	5
225	Data-driven prioritization and preclinical evaluation of therapeutic targets in glioblastoma. <i>Neuro-Oncology Advances</i> , 2020 , 2, vdaa151	0.9	0
224	Clinical management of emotions in patients with cancer: introducing the approach "emotional support and case finding". <i>Translational Behavioral Medicine</i> , 2020 , 10, 1399-1405	3.2	1
223	Olanzapine Versus Haloperidol for Treatment of Delirium in Patients with Advanced Cancer: A Phase III Randomized Clinical Trial. <i>Oncologist</i> , 2020 , 25, e570-e577	5.7	4
222	Combinatorial Immunotherapies for Metastatic Colorectal Cancer. <i>Cancers</i> , 2020 , 12,	6.6	10
221	Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance. <i>Cancers</i> , 2020 , 12,	6.6	3
220	A specific microRNA profile as predictive biomarker for systemic treatment in patients with metastatic colorectal cancer. <i>Cancer Medicine</i> , 2020 , 9, 7558-7571	4.8	6
219	Proteomic Analysis of miR-195 and miR-497 Replacement Reveals Potential Candidates that Increase Sensitivity to Oxaliplatin in MSI/P53wt Colorectal Cancer Cells. <i>Cells</i> , 2019 , 8,	7.9	15
218	Lesion detection by [Zr]Zr-DFO-girentuximab and [F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019 , 46, 1931-1939	8.8	25
217	Phase I Dose-Escalation Study of Once Weekly or Once Every Two Weeks Administration of High-Dose Sunitinib in Patients With Refractory Solid Tumors. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4112-4118	2.2	8
216	INKA, an integrative data analysis pipeline for phosphoproteomic inference of active kinases. <i>Molecular Systems Biology</i> , 2019 , 15, e8250	12.2	26
215	Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6). <i>BMC Cancer</i> , 2019 , 19, 390	4.8	48
214	Accuracy of the Delirium Observational Screening Scale (DOS) as a screening tool for delirium in patients with advanced cancer. <i>BMC Cancer</i> , 2019 , 19, 160	4.8	10

213	Predictors for use of psychosocial services in patients with metastatic colorectal cancer receiving first line systemic treatment. <i>BMC Cancer</i> , 2019 , 19, 115	4.8	6
212	Optimal treatment of opioid induced constipation in daily clinical practice - an observational study. <i>BMC Palliative Care</i> , 2019 , 18, 31	3	2
211	Immuno-PET Imaging to Assess Target Engagement: Experience from Zr-Anti-HER3 mAb (GSK2849330) in Patients with Solid Tumors. <i>Journal of Nuclear Medicine</i> , 2019 , 60, 902-909	8.9	23
210	Constitutively active GSK3 β as a means to bolster dendritic cell functionality in the face of tumour-mediated immune suppression. <i>OncImmunology</i> , 2019 , 8, e1631119	7.2	6
209	RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer. <i>Molecular Oncology</i> , 2019 , 13, 2361-2374	7.9	18
208	Incidence and risk factors for acute kidney injury in head and neck cancer patients treated with concurrent chemoradiation with high-dose cisplatin. <i>BMC Cancer</i> , 2019 , 19, 1066	4.8	8
207	First-in-human imaging of nanoparticle entrapped docetaxel (CPC634) in patients with advanced solid tumors using 89Zr-Df-CPC634 PET/CT.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3093-3093	2.2	2
206	CD276-positive circulating endothelial cells in advanced colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 572-572	2.2	1
205	Screening and Stepped Care Targeting Psychological Distress in Patients With Metastatic Colorectal Cancer: The TES Cluster Randomized Trial. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 911-920	7.3	9
204	Comparison of phosphoproteomic profiles in left- and right-sided colorectal cancers.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 582-582	2.2	
203	How Does a Supervised Exercise Program Improve Quality of Life in Patients with Cancer? A Concept Mapping Study Examining Patients' Perspectives. <i>Oncologist</i> , 2019 , 24, e374-e383	5.7	4
202	Bone-Targeting Radiopharmaceuticals as Monotherapy or Combined With Chemotherapy in Patients With Castration-Resistant Prostate Cancer Metastatic to Bone. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e281-e292	3.3	6
201	Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , 2018 , 19, 616-628	21.7	251
200	A randomised phase II trial of docetaxel versus docetaxel plus carboplatin in patients with castration-resistant prostate cancer who have progressed after response to prior docetaxel chemotherapy: The RECARDO trial. <i>European Journal of Cancer</i> , 2018 , 90, 1-9	7.5	14
199	Platelet function is disturbed by the angiogenesis inhibitors sunitinib and sorafenib, but unaffected by bevacizumab. <i>Angiogenesis</i> , 2018 , 21, 325-334	10.6	16
198	A safety and immunogenicity study of immunization with hVEGF/RFASE in cynomolgus monkeys. <i>Vaccine</i> , 2018 , 36, 2025-2032	4.1	3
197	FDG PET and FES PET Predict PFS on Endocrine Therapy-Letter. <i>Clinical Cancer Research</i> , 2018 , 24, 248	12.9	1
196	Evaluation of several methodological challenges in circulating miRNA qPCR studies in patients with head and neck cancer. <i>Experimental and Molecular Medicine</i> , 2018 , 50, e454	12.8	45

195	The effects of systemic treatment with aminobisphosphonates and statins on circulating VβVβ-T cells in patients with advanced cancer. <i>Immunobiology</i> , 2018 , 223, 171-177	3.4	1
194	Combination of a six microRNA expression profile with four clinicopathological factors for response prediction of systemic treatment in patients with advanced colorectal cancer. <i>PLoS ONE</i> , 2018 , 13, e0201809	3.7	15
193	Selection of Protein Kinase Inhibitors Based on Tumor Tissue Kinase Activity Profiles in Patients with Refractory Solid Malignancies: An Interventional Molecular Profiling Study. <i>Oncologist</i> , 2018 , 23, 1135-e118	5.7	2
192	Serial FLT PET imaging to discriminate between true progression and pseudoprogression in patients with newly diagnosed glioblastoma: a long-term follow-up study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018 , 45, 2404-2412	8.8	13
191	Taste Alterations During Treatment With Protein Kinase Inhibitors: A Pilot Study. <i>Journal of Pain and Symptom Management</i> , 2018 , 56, e1-e4	4.8	1
190	Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody. <i>EJNMMI Research</i> , 2018 , 8, 6	3.6	5
189	Colorectal liver metastases: surgery versus thermal ablation (COLLISION) - a phase III single-blind prospective randomized controlled trial. <i>BMC Cancer</i> , 2018 , 18, 821	4.8	73
188	Metachronous Peritoneal Metastases After Adjuvant Chemotherapy are Associated with Poor Outcome After Cytoreduction and HIPEC. <i>Annals of Surgical Oncology</i> , 2018 , 25, 2347-2356	3.1	16
187	Geriatric Impairments and Low Muscle Mass Are Associated with Treatment Discontinuation and Overall Survival in Newly Diagnosed Non-Transplant Eligible Multiple Myeloma Patients (n-te-NDMM) Treated with Dose-Adjusted Melphalan-Prednisone-Bortezomib (MPV) [Results of the Dutch HOVON 123 Study. <i>Blood</i> , 2018 , 132, 1889-1889	2.2	7
186	Screening and stepped care targeting psychological distress in patients with metastatic colorectal cancer: The TES cluster randomized trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3560-3560	2.2	2
185	Circulating tumor DNA dynamics in resectable gastric cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4069-4069	2.2	1
184	Sorafenib administered using a high-dose, pulsatile regimen in patients with advanced solid malignancies: Results of a phase I exposure escalation study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e14560-e14560	2.2	1
183	A machine-learning approach for the identification of highly predictive germline SNPs as biomarkers for response to bevacizumab in metastatic colorectal cancer using Elastic Net and Lasso.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e15584-e15584	2.2	1
182	Higher Muscle Strength Is Associated with Prolonged Survival in Older Patients with Advanced Cancer. <i>Oncologist</i> , 2018 , 23, 580-585	5.7	44
181	Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2052-2060	2.2	19
180	Effect of Neoadjuvant Chemoradiotherapy on Health-Related Quality of Life in Esophageal or Junctional Cancer: Results From the Randomized CROSS Trial. <i>Journal of Clinical Oncology</i> , 2018 , 36, 268-275	2.2	60
179	Feasibility, validity and reliability of objective smartphone measurements of physical activity and fitness in patients with cancer. <i>BMC Cancer</i> , 2018 , 18, 1052	4.8	15
178	Impact of Patient- and Clinician-Reported Cumulative Toxicity on Quality of Life in Patients With Metastatic Castration-Naïve Prostate Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018 , 16, 1481-1488	7.3	7

177	Cancer Cachexia: Identification by Clinical Assessment versus International Consensus Criteria in Patients with Metastatic Colorectal Cancer. <i>Nutrition and Cancer</i> , 2018 , 70, 1322-1329	2.8	8
176	The predictive value of cumulative toxicity for quality of life in patients with metastatic colorectal cancer during first-line palliative chemotherapy. <i>Cancer Management and Research</i> , 2018 , 10, 3015-3021	3.6	9
175	The value of tumour debulking for patients with extensive multi-organ metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2018 , 103, 160-164	7.5	5
174	Rscreenorm: normalization of CRISPR and siRNA screen data for more reproducible hit selection. <i>BMC Bioinformatics</i> , 2018 , 19, 301	3.6	6
173	Pulsatile high-dose treatment with antiangiogenic tyrosine kinase inhibitors improves clinical antitumor activity. <i>Angiogenesis</i> , 2017 , 20, 287-289	10.6	7
172	Benefits of Using Stereotactic Body Radiotherapy in Patients With Metachronous Oligometastases of Hormone-Sensitive Prostate Cancer Detected by [18F]fluoromethylcholine PET/CT. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, e773-e782	3.3	25
171	Phosphotyrosine-based-phosphoproteomics scaled-down to biopsy level for analysis of individual tumor biology and treatment selection. <i>Journal of Proteomics</i> , 2017 , 162, 99-107	3.9	19
170	A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017 , 44, 1313-1327	8.8	11
169	The influence of different muscle mass measurements on the diagnosis of cancer cachexia. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2017 , 8, 615-622	10.3	47
168	Muscle mass as a target to reduce fatigue in patients with advanced cancer. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2017 , 8, 623-629	10.3	53
167	A Phase 1 Trial of Cabazitaxel Combined With 188Re-Hydroxyethylidene Diphosphonate in Patients With Metastatic Castration-Resistant Prostate Cancer Who Progressed on or After a Docetaxel-Containing Treatment: The ReCab Trial. <i>Clinical Nuclear Medicine</i> , 2017 , 42, 415-420	1.7	2
166	The clinical application of angiostatic therapy in combination with radiotherapy: past, present, future. <i>Angiogenesis</i> , 2017 , 20, 217-232	10.6	20
165	Development of bioluminescent chick chorioallantoic membrane (CAM) models for primary pancreatic cancer cells: a platform for drug testing. <i>Scientific Reports</i> , 2017 , 7, 44686	4.9	36
164	Prevention of VβVβ T Cell Activation by a VβVβ TCR Nanobody. <i>Journal of Immunology</i> , 2017 , 198, 308-317	5.3	8
163	Insight in taste alterations during treatment with protein kinase inhibitors. <i>European Journal of Cancer</i> , 2017 , 86, 125-134	7.5	19
162	A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of VβVβ-T cells. <i>Oncolmmunology</i> , 2017 , 7, e1375641	7.2	34
161	Androgen and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients as a Surrogate for Tissue Biopsies. <i>Journal of Nuclear Medicine</i> , 2017 , 58, 1906-1912	8.9	34
160	Treatment outcome of patients with recurrent glioblastoma multiforme: a retrospective multicenter analysis. <i>Journal of Neuro-Oncology</i> , 2017 , 135, 183-192	4.8	88

159	Identification of patients with cancer with a high risk to develop delirium. <i>Cancer Medicine</i> , 2017 , 6, 1861-1870	10	
158	Patient-Reported Symptom Monitoring During Chemotherapy. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 318, 1935	27.4	
157	Optimal use of anti-EGFR monoclonal antibodies for patients with advanced colorectal cancer: a meta-analysis. <i>Cancer and Metastasis Reviews</i> , 2017 , 36, 395-406	9.6	19
156	Plasma Ghrelin Levels Are Associated with Anorexia but Not Cachexia in Patients with NSCLC. <i>Frontiers in Physiology</i> , 2017 , 8, 119	4.6	11
155	Efficacy of Umbilical Cord Blood Stem Cell-Derived NK Cells in the Treatment of Metastatic Colorectal Cancer. <i>Frontiers in Immunology</i> , 2017 , 8, 87	8.4	29
154	The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments. <i>Frontiers in Immunology</i> , 2017 , 8, 631	8.4	103
153	Identification of novel therapeutic targets in glioblastoma with functional genomic mRNA profiling.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2018-2018	2.2	3
152	A multicenter phase I trial of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814 in patients with solid tumors.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2556-2556	2.2	5
151	A phase 1/2 study of intermittent, high dose sunitinib in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2591-2591	2.2	1
150	The impact of cumulative toxicity on physical quality of life in patients with metastatic colorectal cancer receiving first line chemotherapy.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3564-3564	2.2	1
149	Pharmacokinetics of cetuximab and tumor uptake of 89Zr-cetuximab as potential predictive biomarkers for benefit of cetuximab in patients with advanced colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e15117-e15117	2.2	1
148	A randomized phase II trial of docetaxel plus carboplatin versus docetaxel in patients with castration-resistant prostate cancer who have progressed after response to prior docetaxel chemotherapy: The RECARDO trial.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 166-166	2.2	1
147	(promoter hypermethylation and response to irinotecan in metastatic colorectal cancer. <i>Oncotarget</i> , 2017 , 8, 63140-63154	3.3	12
146	Objective smartphone measurements of physical activity and fitness in patients with cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 132-132	2.2	
145	Efficacy and side effect profile of olanzapine versus haloperidol for symptoms of delirium in hospitalized patients with advanced cancer: A multicenter, investigator-blinded, randomized, controlled trial (RCT).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 231-231	2.2	0
144	Clinical assessment of emotions in patients with cancer: Diagnostic accuracy compared to two reference standards.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 24-24	2.2	
143	Safety and feasibility of adding tumor debulking to palliative chemotherapy in multi-organ metastatic colorectal cancer: The ORCHESTRA trial.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3553-3553	2.2	
142	Change in metabolic tumor activity on 18F-FDG PET after a single dose of cetuximab to predict for treatment benefit, PFS, and OS in patients with advanced colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11519-11519	2.2	

141	Sorafenib administered using a high-dose, pulsatile regimen in patients with advanced solid malignancies: A phase I exposure escalation study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS2620-TPS2620		2.2	2
140	The Drug Rediscovery Protocol (DRUP).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2547-2547		2.2	
139	Phase I Study of Dalteparin in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2017 ,		3.3	6
138	A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer. <i>British Journal of Cancer</i> , 2016 , 115, 940-948		8.7	4
137	Evaluation of potential circulating biomarkers for prediction of response to chemoradiation in patients with glioblastoma. <i>Journal of Neuro-Oncology</i> , 2016 , 129, 221-30		4.8	11
136	Outcome of Colorectal Cancer Patients Treated with Combination Bevacizumab Therapy: A Pooled Retrospective Analysis of Three European Cohorts from the Angiopredict Initiative. <i>Digestion</i> , 2016 , 94, 129-137		3.6	8
135	Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells. <i>Oncolmmunology</i> , 2016 , 5, e110543	7.2		9
134	ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment. <i>Clinical Cancer Research</i> , 2016 , 22, 1642-52		12.9	56
133	Loss of Muscle Mass During Chemotherapy Is Predictive for Poor Survival of Patients With Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1339-44		2.2	208
132	Radiopharmaceuticals for Palliation of Bone Pain in Patients with Castration-resistant Prostate Cancer Metastatic to Bone: A Systematic Review. <i>European Urology</i> , 2016 , 70, 416-26		10.2	42
131	Abstract CT017: A phase I study of guadecitabine (GUA) combined with irinotecan (IRI) in previously treated metastatic colorectal cancer (mCRC) patients 2016 ,			2
130	Androgen receptor and estrogen receptor imaging in patients with metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11553-11553		2.2	1
129	Pharmacokinetic (PK) effects and safety of olaparib in combination with tamoxifen, anastrozole, or letrozole: Phase I study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2562-2562		2.2	2
128	A randomized, phase II study of repeated rhenium-188-HEDP (rhenium) combined with docetaxel versus docetaxel alone in castration resistant prostate cancer (CRPC) metastatic to bone: The Taxium II trial.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5081-5081		2.2	1
127	A phase I trial of cabazitaxel ± rhenium-188-HEDP in patients with metastatic castration resistant prostate cancer who progressed on or after a docetaxel containing treatment.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e16508-e16508		2.2	1
126	The ORCHESTRA trial: A phase III trial of adding tumor debulking to systemic therapy versus systemic therapy alone in multi-organ metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS788-TPS788		2.2	2
125	Early 18F-FDG PET/CT Evaluation Shows Heterogeneous Metabolic Responses to Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer. <i>PLoS ONE</i> , 2016 , 11, e0155178		3.7	4
124	First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors. <i>Oncotarget</i> , 2016 , 7, 80046-80058		3.3	60

123	Mass spectrometry-based phosphoproteomics of tumor needle biopsies from patients (pts) with advanced solid tumors during treatment with protein kinase inhibitors.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11609-11609	2.2	
122	Umbilical cord blood stem cell derived NK cells as universal treatment for metastatic colorectal cancer using EGFR independent killing mechanisms.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e14525-e14525 ^{2,2}		
121	Allogeneic NK cells generated from cord blood as universal treatment for cervical cancer enabled by HLA independent killing mechanisms.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e14526-e14526	2.2	
120	Randomized phase 2 study of gemcitabine and cisplatin with or without vitamin supplementation in patients with advanced esophagogastric cancer (AEGC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, e15555-e15555 ^{2,3}		
119	Does treatment-related toxicity affect quality of life in patients with metastatic colorectal cancer? A systematic review.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e18106-e18106	2.2	
118	Imaging in Colorectal Cancer: Progress and Challenges for the Clinicians. <i>Cancers</i> , 2016 , 8,	6.6	45
117	Alternative scheduling of pulsatile, high dose sunitinib efficiently suppresses tumor growth. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016 , 35, 138	12.8	15
116	Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer. <i>PLoS ONE</i> , 2016 , 11, e0157830	3.7	51
115	Response and toxicity prediction by MALDI-TOF-MS serum peptide profiling in patients with non-small cell lung cancer. <i>Proteomics - Clinical Applications</i> , 2016 , 10, 743-9	3.1	4
114	Highly specific and potently activating V β V δ -T cell specific nanobodies for diagnostic and therapeutic applications. <i>Clinical Immunology</i> , 2016 , 169, 128-138	9	22
113	Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. <i>Clinical Therapeutics</i> , 2016 , 38, 2286-2299	3.5	25
112	Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancer. <i>Experimental and Molecular Medicine</i> , 2016 , 48, e279	12.8	16
111	Reply to L.E. Daly et al. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3817	2.2	3
110	Sunitinib activates Axl signaling in renal cell cancer. <i>International Journal of Cancer</i> , 2016 , 138, 3002-10	7.5	28
109	Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib. <i>Cellular Oncology (Dordrecht)</i> , 2015 , 38, 119-29	7.2	33
108	Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. <i>Lancet Oncology, The</i> , 2015 , 16, 1090-1098 ^{21,7}		1266
107	Effect of Food on the Pharmacokinetics of Olaparib after Oral Dosing of the Capsule Formulation in Patients with Advanced Solid Tumors. <i>Advances in Therapy</i> , 2015 , 32, 510-22	4.1	34
106	Aminobisphosphonates inhibit dendritic cell-mediated antigen-specific activation of CD1d-restricted iNKT cells. <i>Clinical Immunology</i> , 2015 , 158, 92-9	9	2

105	Feasibility of label-free phosphoproteomics and application to base-line signaling of colorectal cancer cell lines. <i>Journal of Proteomics</i> , 2015 , 127, 247-58	3.9	34
104	Evaluation of different phospho-tyrosine antibodies for label-free phosphoproteomics. <i>Journal of Proteomics</i> , 2015 , 127, 259-63	3.9	31
103	The effect of individualized nutritional counseling on muscle mass and treatment outcome in patients with metastatic colorectal cancer undergoing chemotherapy: a randomized controlled trial protocol. <i>BMC Cancer</i> , 2015 , 15, 98	4.8	13
102	Neo-adjuvant chemotherapy followed by surgery versus surgery alone in high-risk patients with resectable colorectal liver metastases: the CHARISMA randomized multicenter clinical trial. <i>BMC Cancer</i> , 2015 , 15, 180	4.8	36
101	Phase I Clinical Trial to Determine the Feasibility and Maximum Tolerated Dose of Panitumumab to Standard Gemcitabine-Based Chemoradiation in Locally Advanced Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 4569-75	12.9	10
100	CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients. <i>Clinical Cancer Research</i> , 2015 , 21, 2753-62	12.9	38
99	Prophylactic treatment for delayed chemotherapy-induced nausea and vomiting after non-AC based moderately emetogenic chemotherapy: a systematic review of randomized controlled trials. <i>Supportive Care in Cancer</i> , 2015 , 23, 2499-506	3.9	9
98	Molecular imaging of targeted therapies with positron emission tomography: the visualization of personalized cancer care. <i>Cellular Oncology (Dordrecht)</i> , 2015 , 38, 49-64	7.2	19
97	Dried blood spot analysis for therapeutic drug monitoring of pazopanib. <i>Journal of Clinical Pharmacology</i> , 2015 , 55, 1344-50	2.9	22
96	Screening and treatment of psychological distress in patients with metastatic colorectal cancer: study protocol of the TES trial. <i>BMC Cancer</i> , 2015 , 15, 302	4.8	14
95	Platelets: an unexploited data source in biomarker research. <i>Lancet Haematology, the</i> , 2015 , 2, e512-3	14.6	11
94	What is the benefit of treatment with multiple lines of chemotherapy for patients with metastatic breast cancer? A retrospective cohort study. <i>Cancer Epidemiology</i> , 2015 , 39, 848-53	2.8	7
93	Vaccination approach to anti-angiogenic treatment of cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2015 , 1855, 155-71	11.2	18
92	Bevacizumab in combination with radiotherapy and temozolomide for patients with newly diagnosed glioblastoma multiforme. <i>Oncologist</i> , 2015 , 20, 107-8	5.7	18
91	New Treatment Options for Patients With Metastatic Prostate Cancer: What Is The Optimal Sequence?. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 271-279	3.3	31
90	Abstract 2496: Preclinical testing of a novel anti-angiogenic vaccine targeting human VEGF 2015 ,		2
89	Abstract OT3-2-01: IMPACT: IMaging PATients for Cancer drug selectiOn [Metastatic breast cancer (MBC) 2015 ,		4
88	Effect of itraconazole and rifampin on the pharmacokinetics of olaparib tablet formulation in patients with advanced solid tumours: Phase I open-label studies.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2565-2565	2.2	1

87	CEA-targeted engineered IL2: Clinical confirmation of tumor targeting and evidence of intra-tumoral immune activation.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3016-3016	2.2	9
86	A novel combinatorial therapy using cytolytic NK cells and anti-EGFR moAb to improve the treatment of EGFR expressing solid tumors.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e14017-e14017	2.2	1
85	Phase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion for relapsed/refractory gastrointestinal (GI) adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS3097-TPS3097	2.2	1
84	The Potential Role of Lysosomal Sequestration in Sunitinib Resistance of Renal Cell Cancer. <i>Journal of Kidney Cancer and VHL</i> , 2015 , 2, 195-203	1.4	12
83	⁸⁹ Zr-cetuximab PET imaging in patients with advanced colorectal cancer. <i>Oncotarget</i> , 2015 , 6, 30384-93	3.3	82
82	A phase I study of investigational agent SGI-110 combined with irinotecan in previously treated metastatic colorectal cancer patients.. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS797-TPS797	2.2	1
81	Allowance of tumor-educated platelets for multiclass liquid biopsy-based diagnosis of cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 11058-11058	2.2	
80	Comparison of deep sequencing miRNA expression analysis in primary colorectal cancer and paired metastases.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e14682-e14682	2.2	
79	A phase 1 study of weekly high dose sunitinib in patients with advanced solid tumors: Early signs of activity in non-RCC tumor types.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e13550-e13550	2.2	
78	The ORCHESTRA trial: A phase III trial of adding tumor debulking to systemic therapy versus systemic therapy alone in (mCRC) multi-organ metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS3631-TPS3631	2.2	
77	High-level copy number gains of established and potential drug target genes in gastric cancer as a lead for treatment development and selection. <i>Cellular Oncology (Dordrecht)</i> , 2014 , 37, 41-52	7.2	11
76	A novel splice site mutation in the noncoding region of BRCA2: implications for Fanconi anemia and familial breast cancer diagnostics. <i>Human Mutation</i> , 2014 , 35, 442-6	4.7	6
75	Mass spectrometry-based serum and plasma peptidome profiling for prediction of treatment outcome in patients with solid malignancies. <i>Oncologist</i> , 2014 , 19, 1028-39	5.7	17
74	Bispecific antibody platforms for cancer immunotherapy. <i>Critical Reviews in Oncology/Hematology</i> , 2014 , 92, 153-65	7	68
73	Clinical evaluation of the efficacy of methylxaltrexone in resolving constipation induced by different opioid subtypes combined with laboratory analysis of immunomodulatory and antiangiogenic effects of methylxaltrexone. <i>BMC Palliative Care</i> , 2014 , 13, 42	3	12
72	ShrinkBayes: a versatile R-package for analysis of count-based sequencing data in complex study designs. <i>BMC Bioinformatics</i> , 2014 , 15, 116	3.6	25
71	Analysis of AKT and ERK1/2 protein kinases in extracellular vesicles isolated from blood of patients with cancer. <i>Journal of Extracellular Vesicles</i> , 2014 , 3, 25657	16.4	24
70	Optimal Human Blood Sampling for Platelet Research. <i>Current Angiogenesis</i> , 2014 , 2, 157-161		5

69	Mass spectrometry-based proteomics: from cancer biology to protein biomarkers, drug targets, and clinical applications. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014 , e504-10	7.1	28
68	VβVβ-T cells as antigen presenting cells for iNKT cell based cancer immunotherapy. <i>Onc Immunology</i> , 2014 , 3, e955343	7.2	1
67	Genomic landscape of metastatic colorectal cancer. <i>Nature Communications</i> , 2014 , 5, 5457	17.4	49
66	CD1d-restricted antigen presentation by VβVβ-T cells requires trogocytosis. <i>Cancer Immunology Research</i> , 2014 , 2, 732-40	12.5	15
65	Predictive biomarkers in renal cell cancer: insights in drug resistance mechanisms. <i>Drug Resistance Updates</i> , 2014 , 17, 77-88	23.2	43
64	Lymph node retrieval during esophagectomy with and without neoadjuvant chemoradiotherapy: prognostic and therapeutic impact on survival. <i>Annals of Surgery</i> , 2014 , 260, 786-92; discussion 792-3	7.8	97
63	Prediction of treatment-related toxicity and outcome with geriatric assessment in elderly patients with solid malignancies treated with chemotherapy: a systematic review. <i>Annals of Oncology</i> , 2014 , 25, 1914-1918	10.3	52
62	Abstract CT216: Phase I dose escalating study of 2B3-101, glutathione PEGylated liposomal doxorubicin, in patients with solid tumors and brain metastases or recurrent malignant glioma 2014		11
61	ImmunoPET imaging with 89Zr-cetuximab in patients with advanced colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 11102-11102	2.2	2
60	A phase I study of DMOT4039A, an antibody-drug conjugate (ADC) targeting mesothelin (MSLN), in patients (pts) with unresectable pancreatic (PC) or platinum-resistant ovarian cancer (OC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2529-2529	2.2	4
59	Effect of food on the pharmacokinetics (PK) of olaparib after oral dosing of the capsule formulation.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2599-2599	2.2	1
58	Identification of patients at risk for delirium on a medical oncology hospital ward.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 130-130	2.2	1
57	Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasculature. <i>Oncoscience</i> , 2014 , 1, 844-53	0.8	25
56	Phase I study of dalteparin in combination with sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e15607-e15607	2.2	
55	Mass spectrometry-based serum and plasma peptide profiling for prediction of treatment outcome in patients with cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e22221-e22221	2.2	
54	Proteomics in colorectal cancer translational research: biomarker discovery for clinical applications. <i>Clinical Biochemistry</i> , 2013 , 46, 466-79	3.5	70
53	Analysis of the novel fanconi anemia gene SLX4/FANCP in familial breast cancer cases. <i>Human Mutation</i> , 2013 , 34, 70-3	4.7	17
52	Novel strategies towards the use of anti-angiogenic agents in breast cancer. <i>European Journal of Pharmacology</i> , 2013 , 717, 36-9	5.3	4

51	Aiming for a better understanding and management of cancer-related fatigue. <i>Oncologist</i> , 2013 , 18, 1135-43	5.7	43	51
50	Successful treatment of renal cell carcinoma with sorafenib after effective but hepatotoxic sunitinib exposure. <i>Journal of Clinical Oncology</i> , 2013 , 31, e83-6	2.2		12
49	Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors. <i>Epigenetics</i> , 2013 , 8, 907-20	5.7		28
48	The future of colorectal cancer: implications of screening. <i>Gut</i> , 2013 , 62, 1387-9	19.2		6
47	Tumor, skin, and plasma concentrations of protein kinase inhibitors (PKIs) in patients with advanced cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 11087-11087	2.2		2
46	Association of DNA promoter hypermethylation of decoy receptor 1 (DCR1) with poor response to irinotecan in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3552-3552	2.2		
45	Genome-wide methylation profiling to identify potential epigenetic biomarkers associated with response to sunitinib in metastatic renal cell cancer (mRCC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4566-4566	2.2		1
44	Weight loss of 5% or more predicts loss of fat-free mass during palliative chemotherapy in patients with advanced cancer: a pilot study. <i>Nutrition and Cancer</i> , 2012 , 64, 826-32	2.8		25
43	Activated iNKT cells promote V β V α -T cell anti-tumor effector functions through the production of TNF- β . <i>Clinical Immunology</i> , 2012 , 142, 194-200	9		15
42	Gram-positive bacteria: a major microbial burn-on for invariant NKT cells. <i>Immunotherapy</i> , 2012 , 4, 19	3.8		1
41	Losses of chromosome 5q and 14q are associated with favorable clinical outcome of patients with gastric cancer. <i>Oncologist</i> , 2012 , 17, 653-62	5.7		22
40	Circulating invariant natural killer T-cell numbers predict outcome in head and neck squamous cell carcinoma: updated analysis with 10-year follow-up. <i>Journal of Clinical Oncology</i> , 2012 , 30, 567-70	2.2		44
39	Reversible posterior leukoencephalopathy syndrome during sunitinib therapy for metastatic renal cell carcinoma. <i>Oncology Letters</i> , 2012 , 3, 1293-1296	2.6		15
38	Targeting JNK-interacting-protein-1 (JIP1) sensitises osteosarcoma to doxorubicin. <i>Oncotarget</i> , 2012 , 3, 1169-81	3.3		32
37	Response prediction by MALDI-TOF-MS serum peptide profiling of combination treatment with sorafenib and erlotinib in patients with non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e18094-e18094	2.2		
36	Bulldozing linked glycolipids for recognition by invariant NKT cells. <i>Immunotherapy</i> , 2012 , 4, 20	3.8		
35	An β -galactosylceramide nose job shapes up iNKT cells. <i>Immunotherapy</i> , 2012 , 4, 20-1	3.8		
34	Surgery of the primary in stage IV colorectal cancer with unresectable metastases. <i>European Journal of Cancer</i> , 2011 , 47 Suppl 3, S61-6	7.5		29

33	Clinical experience with β -galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection. <i>Clinical Immunology</i> , 2011 , 140, 130-41	9	75
32	Severe toxicity of capecitabine following uncomplicated treatment with 5-fluorouracil/leucovorin. <i>Medical Oncology</i> , 2011 , 28, 1136-9	3.7	3
31	Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review. <i>Angiogenesis</i> , 2011 , 14, 135-41	10.6	52
30	Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. <i>Clinical Cancer Research</i> , 2011 , 17, 7337-46	12.9	232
29	Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , 2010 , 16, 2187-97	12.9	11
28	The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. <i>Clinical Cancer Research</i> , 2010 , 16, 1613-23	12.9	179
27	Subnuclear proteomics in colorectal cancer: identification of proteins enriched in the nuclear matrix fraction and regulation in adenoma to carcinoma progression. <i>Molecular and Cellular Proteomics</i> , 2010 , 9, 988-1005	7.6	55
26	The relationship of vascular endothelial growth factor and coagulation factor (fibrin and fibrinogen) expression in clear cell renal cell carcinoma. <i>Urology</i> , 2010 , 75, 608-14	1.6	32
25	Strategies for kinome profiling in cancer and potential clinical applications: chemical proteomics and array-based methods. <i>Analytical and Bioanalytical Chemistry</i> , 2010 , 397, 3163-71	4.4	27
24	Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?. <i>Angiogenesis</i> , 2010 , 13, 1-14	10.6	330
23	Signalling pathways in vasculogenic mimicry. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2010 , 1806, 18-28	11.2	97
22	Case 19-2009: Carcinoma of the gastroesophageal junction. <i>New England Journal of Medicine</i> , 2009 , 361, 1315; author reply 1315-6	59.2	
21	Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib. <i>Angiogenesis</i> , 2009 , 12, 69-79	10.6	51
20	Proteomics of the TRAP-induced platelet releasate. <i>Journal of Proteomics</i> , 2009 , 72, 91-109	3.9	97
19	Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib. <i>Drug Resistance Updates</i> , 2009 , 12, 114-26	23.2	167
18	Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors. <i>Clinical Cancer Research</i> , 2008 , 14, 3589-97	12.9	99
17	A multiple-loop, double-cube microarray design applied to prostate cancer cell lines with variable sensitivity to histone deacetylase inhibitors. <i>Clinical Cancer Research</i> , 2008 , 14, 6886-94	12.9	11
16	Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. <i>Nature Reviews Cancer</i> , 2007 , 7, 475-85	31.3	418

15	Sequence-dependent antitumor effects of differentiation agents in combination with cell cycle-dependent cytotoxic drugs. <i>Cancer Chemotherapy and Pharmacology</i> , 2007 , 60, 329-39	3.5	19
14	Platelets take up the monoclonal antibody bevacizumab. <i>Clinical Cancer Research</i> , 2007 , 13, 5341-7	12.9	89
13	Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model. <i>Clinical Cancer Research</i> , 2007 , 13, 4201-8	12.9	107
12	Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma. <i>Clinical Cancer Research</i> , 2007 , 13, 4538-46	12.9	76
11	Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. <i>Cancer Research</i> , 2006 , 66, 8814-21	10.1	260
10	Inhibition of angiogenesis in cancer patients. <i>Expert Opinion on Emerging Drugs</i> , 2005 , 10, 403-12	3.7	16
9	Angiogenesis inhibitors: what is the clinical future?. <i>Progress in Drug Research Fortschritte Der Arzneimittelforschung Progres Des Recherches Pharmaceutiques</i> , 2005 , 63, 67-91		1
8	Circulating endothelial cells in cancer patients do not express tissue factor. <i>Cancer Letters</i> , 2004 , 213, 241-8	9.9	21
7	Vascular endothelial growth factor-165 overexpression stimulates angiogenesis and induces cyst formation and macrophage infiltration in human ovarian cancer xenografts. <i>American Journal of Pathology</i> , 2002 , 160, 537-48	5.8	72
6	Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intratumoral fluid. <i>Clinical Cancer Research</i> , 2002 , 8, 3747-54	12.9	56
5	Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets. <i>Blood</i> , 2000 , 96, 4216-4221	2.2	165
4	The role of vascular endothelial growth factor (VEGF) in tumor angiogenesis and early clinical development of VEGF-receptor kinase inhibitors. <i>Clinical Breast Cancer</i> , 2000 , 1 Suppl 1, S80-4	3	59
3	Treatment of the Kasabach-Merritt syndrome with pegylated recombinant human megakaryocyte growth and development factor in mice: elevated platelet counts, prolonged survival, and tumor growth inhibition. <i>Pediatric Research</i> , 1999 , 46, 562-5	3.2	14
2	Effects of chemotherapy on pathologic and biologic characteristics of locally advanced breast cancer. <i>American Journal of Clinical Pathology</i> , 1997 , 107, 211-8	1.9	90
1	INKA, an integrative data analysis pipeline for phosphoproteomic inference of active phosphokinases		1